中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (2): 116-118.doi: 10.12144/zgmfskin202602116

• 病例报告 • 上一篇    下一篇

度普利尤单抗治疗儿童获得性大疱性表皮松解症一例

魏艳杰1,2,张鲁1,3,钏锦涛1,2,张佩莲1,2   

  1. 1云南中医药大学第一附属医院，云南昆明，650021; 2云南省中医院皮肤科，云南昆明，650021; 3山东省烟台市奇山医院皮肤科，山东烟台，264000
  • 出版日期:2026-02-15 发布日期:2026-01-28

Treatment of epidermolysis bullosa acquisita with dupilumab in a child: a case report

WEI Yanjie1,2, ZHANG Lu1,3, CHUAN Jintao1,2, ZHANG Peilian1,2   

  1. 1 Department of Dermatology, the First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming 650021, China; 2 Department of Dermatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650021, China; 3 Department of Dermatology, Qishan Hospital of Yantai, Yantai 264000, China
  • Online:2026-02-15 Published:2026-01-28

PDF (PC)

9

摘要： 既往个案报道度普利尤单抗可在短时间内控制获得性大疱性表皮松解症(epidermolysis bullosa acquisita,EBA)病情。本例EBA患儿7岁，长期使用糖皮质激素，皮损控制不佳，基于既往个案报道，给予度普利尤单抗联合甲泼尼龙片8 mg/d治疗，12周后，原有皮损干涸、结痂，口腔黏膜糜烂面缩小，仅在摩擦部位偶有新发皮损，瘙痒明显好转。目前糖皮质激素已减量至4 mg/d，仍在随访中。

关键词: 儿童, 获得性大疱性表皮松解症, 度普利尤单抗

Abstract: Previous case reports have demonstrated that dupilumab can achieve rapid disease control in epidermolysis bullosa acquisita (EBA). In this case, a 7-year-old child with EBA showed poor response to long-term glucocorticoid therapy. Based on prior case reports, the patient was administered dupilumab in combination with methylprednisolone tablets 8 mg/day. After 12 weeks of treatment, the existing skin lesions dried up and formed crusts, the erosive lesions on the oral mucosa regressed, occasional new lesions only appeared at friction-prone sites, and pruritus was significantly alleviated. Currently, the glucocorticoid dose has been tapered to 4 mg/day, and the patient remains under continuous follow-up.

Key words: child, epidermolysis bullosa acquisita, dupilumab